Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
about
Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literaturePegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo.Engineered polymers for advanced drug delivery.Dermatologic manifestations of cytotoxic therapy.Epirubicin permeation of personal protective equipment can induce apoptosis in keratinocytes.
P2860
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@ast
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@en
type
label
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@ast
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@en
prefLabel
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@ast
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@en
P2093
P2860
P1476
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
@en
P2093
James W Patterson
Joseph C English
Rachel Toney
P2860
P304
P356
10.1034/J.1600-0560.2003.00113.X
P577
2003-10-01T00:00:00Z